Identifying how to best treat patients who develop resistance to EGFR-targeted therapy, especially frontline osimertinib (Tagrisso), is part of the next chapter of research in this molecularly driven non–small cell lung cancer (NSCLC) arena, explained Christina Baik, MD, MPH.
“It’s important to understand that there is now another option in the space [with frontline osimertinib],” said Baik. “There is also some debate in terms of adding EGFR inhibitors to TKIs. People should be familiar with some of the work that is being done for patients at the time of progression, as well as some of the therapies that are being developed after osimertinib.”
One such research effort is the platform phase 2 ORCHARD trial (NCT03944772), in which at time of progression on frontline osimertinib, patients with EGFR-mutant NSCLC are then segmented into different study arms of various combination regimens with osimertinib, based on biomarker-positive status.
In an interview with OncLive® during the 2020 Institutional Perspectives in Cancer webinar on Lung Cancer, Baik, a physician at Seattle Cancer Care Alliance, an associate professor of medicine at the University of Washington School of Medicine, who is also an associate professor in the Clinical Research Division at Fred Hutchinson Cancer Research Center highlighted the evolving role of EGFR inhibition in the NSCLC space. Read more.